16.97
0.06 (0.35%)
| Previous Close | 16.91 |
| Open | 16.92 |
| Volume | 198,317 |
| Avg. Volume (3M) | 316,276 |
| Market Cap | 629,513,792 |
| Price / Sales | 7.57 |
| Price / Book | 3.83 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | -62.50% |
| Operating Margin (TTM) | -69.33% |
| Diluted EPS (TTM) | -1.25 |
| Quarterly Revenue Growth (YOY) | 42.30% |
| Total Debt/Equity (MRQ) | 12.03% |
| Current Ratio (MRQ) | 17.36 |
| Operating Cash Flow (TTM) | -36.90 M |
| Levered Free Cash Flow (TTM) | -26.02 M |
| Return on Assets (TTM) | -17.46% |
| Return on Equity (TTM) | -41.39% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | CeriBell, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | -4.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -1.10 |
|
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| % Held by Insiders | 10.54% |
| % Held by Institutions | 84.45% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Yu Fan | 30 Sep 2025 | 1,353,166 |
| Abg-Wtt Global Life Science Capital Partners Gp Ltd | 30 Sep 2025 | 1,088,101 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 20.00 (TD Cowen, 17.86%) | Buy |
| Median | 19.00 (11.96%) | |
| Low | 17.00 (JP Morgan, 0.18%) | Buy |
| Average | 18.67 (10.02%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 12.31 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 05 Nov 2025 | 17.00 (0.18%) | Buy | 11.78 |
| TD Cowen | 05 Nov 2025 | 20.00 (17.86%) | Buy | 11.78 |
| Raymond James | 21 Oct 2025 | 19.00 (11.96%) | Buy | 13.38 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CHAO XINGJUAN | - | 16.66 | -25,000 | -416,500 |
| ROBERTSON REBECCA B | - | 16.85 | -827 | -13,935 |
| WOO RAYMOND | - | 16.66 | -11,112 | -185,126 |
| Aggregate Net Quantity | -36,939 | |||
| Aggregate Net Value ($) | -615,561 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 16.72 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ROBERTSON REBECCA B | Director | 02 Dec 2025 | Automatic sell (-) | 827 | 16.85 | 13,935 |
| CHAO XINGJUAN | Officer | 01 Dec 2025 | Automatic sell (-) | 25,000 | 16.66 | 416,500 |
| CHAO XINGJUAN | Officer | 01 Dec 2025 | Option execute | 25,000 | - | - |
| WOO RAYMOND | Officer | 01 Dec 2025 | Automatic sell (-) | 11,112 | 16.66 | 185,126 |
| WOO RAYMOND | Officer | 01 Dec 2025 | Option execute | 11,112 | - | - |
| Date | Type | Details |
|---|---|---|
| 24 Nov 2025 | Announcement | Ceribell Receives FDA 510(k) Clearance for Use of ClarityⓇ Algorithm for Neonates |
| 19 Nov 2025 | Announcement | Ceribell to Participate in the Piper Sandler 37th Annual Healthcare Conference |
| 06 Nov 2025 | Announcement | Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum |
| 04 Nov 2025 | Announcement | Ceribell Reports Third Quarter 2025 Financial Results |
| 21 Oct 2025 | Announcement | Ceribell to Report Third Quarter 2025 Financial Results on November 4, 2025 |
| 22 Sep 2025 | Announcement | Medtech Leader Erica Rogers Joins Ceribell Board of Directors |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |